Payment overview · 2025
General Payments
$63.96
2 reported records · 1 companies
Healthcare provider profile · identity verified
Christine E. Pierre, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WORCESTER, MA · NPI 1437599172
Verified facts
What the public records show
CMS Open Payments records show Christine E. Pierre, M.D. received $63.96 in general payments during 2025 across 2 reported records.
Astellas Pharma US Inc accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Myrbetriq by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $63.96 | 100.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $63.96 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cresemba Normalized: cresemba |
Drug | Astellas Pharma US Inc | $63.96 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 517 | 57 |
| Furosemide | Furosemide | 446 | 56 |
| Atorvastatin Calcium | Atorvastatin Calcium | 394 | 77 |
| Trazodone Hcl | Trazodone Hcl | 342 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 318 | 48 |
| Gabapentin | Gabapentin | 300 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 254 | 50 |
| Sertraline Hcl | Sertraline Hcl | 198 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 170 | 40 |
| Mirtazapine | Mirtazapine | 170 | 28 |
| Losartan Potassium | Losartan Potassium | 157 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 143 | 39 |
| Potassium Chloride | Potassium Chloride | 142 | 27 |
| Jardiance | Empagliflozin | 133 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 132 | 20 |
| Lisinopril | Lisinopril | 122 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 118 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 17 |
| Torsemide | Torsemide | 107 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 105 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 15 |
| Donepezil Hcl | Donepezil Hcl | 79 | 12 |
| Baclofen | Baclofen | 76 | 12 |
| Xarelto | Rivaroxaban | 75 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 74 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 12 |
| Simvastatin | Simvastatin | 73 | 14 |
| Famotidine | Famotidine | 71 | 14 |
| Metformin Hcl | Metformin Hcl | 70 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 19 |
| Memantine Hcl | Memantine Hcl | 63 | suppressed |
| Olanzapine | Olanzapine | 63 | 12 |
| Omeprazole | Omeprazole | 62 | 23 |
| Azithromycin | Azithromycin | 58 | 11 |
| Prednisone | Prednisone | 58 | 20 |
| Ondansetron Odt | Ondansetron | 56 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 52 | suppressed |
| Allopurinol | Allopurinol | 51 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | suppressed |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Latanoprost | Latanoprost | 49 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 48 | suppressed |
| Risperidone | Risperidone | 48 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | suppressed |
| Carvedilol | Carvedilol | 46 | suppressed |
| Lactulose | Lactulose | 46 | 18 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 45 | 43 |
| Divalproex Sodium | Divalproex Sodium | 44 | suppressed |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 40 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 40 | 20 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 38 | suppressed |
| Spironolactone | Spironolactone | 37 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 36 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Lorazepam | Lorazepam | 32 | 21 |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Nyamyc | Nystatin | 23 | 12 |
| Sucralfate | Sucralfate | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | 17 |
| Trimethoprim | Trimethoprim | 20 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 19 | 19 |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Budesonide | Budesonide | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Carbidopa | Carbidopa | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Procrit | Epoetin Alfa | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $63.96 · 2 records | Astellas Pharma US Inc | Cresemba | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error